Company Overview and News

 
United Breweries Limited - Shareholders meeting

2018-09-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UBL UBHOLDINGS 507458 UNBWY 532478

 
Nifty likely to remain under pressure; United Breweries among top 5 stocks to buy for up to 17% return

2018-09-18 moneycontrol
For third consecutive Monday, the market witnessed a negative start to the week on trade wars tension and weakness in rupee. Government measures announced over the weekend arrested the currency decline but failed to enthuse the markets.
505200 ECQRY TORNTPHARM TQRRY UBL 500420 UBHOLDINGS 507458 UNBWY EICHERMOT 532478

 
United Breweries Limited - Updates

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UBL UBHOLDINGS 507458 UNBWY 532478

5
 
An evening walk down Dalal Street | Selling across the board drags Nifty below 11,600, Sensex closes over 300 points lower

2018-09-03 moneycontrol
It was an anti-climax for the market on Monday, as benchmarks closed nowhere near to the levels they had opened at. In fact, a sharp selloff in the last hour erased all the gains, with the market closing at low points of the day. The Nifty managed to give up 11,600, while the Sensex fell around 300 points.
BAJAJ-AUTO AXB IBN UBL 533262 UBHOLDINGS 532977 HIN UNBWY 532215 532478 AXBKY AXBA ICICIBANK RAMKY BAJFINANCE AXISBANK 532174 BJJQY 500185 507458 HCC 500034

 
United Breweries down 1% as Kotak Securities maintains sell with target of Rs 1,100

2018-09-03 moneycontrol
Shares of United Breweries was down 1.3 percent intraday Monday as research house Kotak Securities has maintained sell with a target price of Rs 1,100.
UBL UBHOLDINGS 507458 UNBWY 532478

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

14m - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...